Chandigarh Herald

70+ Active Companies working to develop 70+ Pipeline Therapies for Fallopian Tube Cancer Treatment

 Breaking News
  • No posts were found

70+ Active Companies working to develop 70+ Pipeline Therapies for Fallopian Tube Cancer Treatment

April 14
20:55 2023
70+ Active Companies working to develop 70+ Pipeline Therapies for Fallopian Tube Cancer Treatment

DelveInsight’s, “Fallopian Tube Cancer Pipeline Insight 2023,” report provides comprehensive insights about 70+ Fallopian tube cancer companies and 70+ pipeline drugs in the Fallopian Tube Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The fallopian tube cancer pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Fallopian Tube Cancer Emerging drugs, the Fallopian Tube Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Fallopian Tube Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Fallopian Tube Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Fallopian Tube Cancer clinical trials studies, Fallopian Tube Cancer NDA approvals (if any), and product development activities comprising the technology, Fallopian Tube Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Fallopian Tube Cancer Pipeline Report

 

  • DelveInsight’s fallopian tube cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for fallopian tube cancer treatment.

 

  • The leading Fallopian Tube Cancer Companies include ImmunoGen,  OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others 

 

  • Promising fallopian tube cancer pipeline therapies include Mirvetuximab Soravtansine, Trabectedin, Navicixizumab, Pembrolizumab, Nemvaleukin, DCVAC/OvCa, Fluzoparib, AL3818, Oregovomab, Enzalutamide, PF-06873600, PankoMab-GEX, VTX-2337, Guadecitabine, Gimatecan, tisotumab vedotin, SG001, ZEN003694, AVOVA-1, Abemaciclib, XmAb20717, Entinostat, DPX-Survivac, GEN-1, ATX-101, GRN-300, TG4050, CART-TnMUC1, Olvimulogene nanivacirepvec, ONC-392, Oregovomab, ZN-c3, ART0380, IMGN151, SL-172154, TG4050, STRO-002, XMT-1660, RP12146, ATRC-101,  and others.

 

  • The Fallopian Tube Cancer companies and academics are working to assess challenges and seek opportunities that could influence Fallopian Tube Cancer R&D. The therapies under development are focused on novel approaches for Fallopian Tube Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Fallopian Tube Cancer Pipeline landscape @ Fallopian Tube Cancer Pipeline Outlook Report

 

Fallopian Tube Cancer Overview

Fallopian Tube Cancer starts in the fallopian tubes, which connect a woman’s ovaries to their uterus. Fallopian Tube Cancer is very rare. Only about 1% of all reproductive cancers in women start in the fallopian tubes. The causes and risk factors for developing primary Fallopian Tube Cancer are not known.

 

Recent Developmental Activities in the Fallopian Tube Cancer Treatment Landscape

 

  • Mirvetuximab soravtansine being developed by ImmunoGen is a first-in-class antibody-drug conjugate which consists of a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, in order to kill the targeted cancer cells. SORAYA is a global, single-arm, phase III study evaluating mirvetuximab soravtansine in adults with folate receptor alpha–high, platinum-resistant, high-grade, serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. As per the results, Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers.

 

  • SL-172154 is a bi-functional fusion protein that targets CD47 on malignant cells and CD40 on immune cells (antigen presenting cells). In August 2022, Shattuck Labs initiated a SL03-OHD-105 an open-label, multicenter, phase Ib trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer.

 

  • ATX-101, the lead compound of APIM’s development program, is being evaluated in combination with platinum-based chemotherapy in patients suffering from recurrent, platinum sensitive ovarian, fallopian tube and primary peritoneal cancer in Phase I/II stage of developement. In May 2021, US FDA accepted its Investigational New Drug application (IND) for a Phase I/II clinical trial.

 

  • IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). In October 2022, ImmunoGen initiated a Phase I, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

 

For further information, refer to the detailed Fallopian Tube Cancer Drugs Launch, Fallopian Tube Cancer Developmental Activities, and Fallopian Tube Cancer News, click here for Fallopian Tube Cancer Ongoing Clinical Trial Analysis

 

Fallopian Tube Cancer Emerging Drugs Profile

 

  • Mirvetuximab Soravtansine: ImmunoGen

Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.

 

  • Tisotumab vedotin: Genmab/Seagen

Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody–drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.

 

  • Pembrolizumab: Merck & Co.

Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.

 

Fallopian Tube Cancer Pipeline Therapeutics Assessment

There are approx. 70+ key Fallopian Tube Cancer companies which are developing the Fallopian Tube Cancer therapies. The companies which have their Fallopian Tube Cancer drug candidates in the most advanced stage, i.e. Phase III include, Immunogen.

 

Find out more about the Fallopian Tube Cancer Pipeline Segmentation, Therapeutics Assessment, and Fallopian Tube Cancer Emerging Drugs @ Fallopian Tube Cancer Treatment Landscape

 

Scope of the Fallopian Tube Cancer Pipeline Report

 

  • Coverage- Global

 

  • Fallopian Tube Cancer Companies- ImmunoGen,  OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee’s Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others. 

 

  • Fallopian Tube Cancer Pipeline therapies- Mirvetuximab Soravtansine, Trabectedin, Navicixizumab, Pembrolizumab, Nemvaleukin, DCVAC/OvCa, Fluzoparib, AL3818, Oregovomab, Enzalutamide, PF-06873600, PankoMab-GEX, VTX-2337, Guadecitabine, Gimatecan, tisotumab vedotin, SG001, ZEN003694, AVOVA-1, Abemaciclib, XmAb20717, Entinostat, DPX-Survivac, GEN-1, ATX-101, GRN-300, TG4050, CART-TnMUC1, Olvimulogene nanivacirepvec, ONC-392, Oregovomab, ZN-c3, ART0380, IMGN151, SL-172154, TG4050, STRO-002, XMT-1660, RP12146, ATRC-101,  and others.

 

  • Fallopian Tube Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Fallopian Tube Cancer Pipeline Companies and Therapies, click here @ Fallopian Tube Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Fallopian Tube Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Fallopian Tube Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Fallopian Tube Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Mirvetuximab Soravtansine: ImmunoGen
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II) 
  13. Gimatecan: Lee’s Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. TG4050: Transgene
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Fallopian Tube Cancer Key Companies
  20. Fallopian Tube Cancer Key Products
  21. Fallopian Tube Cancer- Unmet Needs
  22. Fallopian Tube Cancer- Market Drivers and Barriers
  23. Fallopian Tube Cancer- Future Perspectives and Conclusion
  24. Fallopian Tube Cancer Analyst Views
  25. Fallopian Tube Cancer Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Fallopian Tube Cancer Mergers and acquisitions, Fallopian Tube Cancer Licensing Activities @ Fallopian Tube Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/